{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:16Z","timestamp":1791920836341,"version":"4.3.4"},"reference-count":53,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Dolutegravir (DTG) is widely recommended within three\u2010drug regimens. However, similar efficacy and tolerability have also been achieved with DTG within two\u2010drug regimens in clinical trials. This study evaluated the real\u2010world effectiveness and discontinuations in people living with HIV\u20101 (PLHIV) switching to DTG with lamivudine (3TC) or rilpivirine (RPV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a one\u2010arm meta\u2010analysis utilizing data from a systematic literature review. Data from real\u2010world evidence studies of DTG\u00a0+\u00a0RPV and DTG\u00a0+\u00a03TC were extracted, pooled and analysed. The primary outcome was the proportion of patients with viral failure (VF; \u2265\u00a050 copies\/mL in two consecutive measurements and\/or\u00a0\u2265\u00a01000 copies\/mL in a single measurement) at week 48 (W48) and week 96 (W96). Other outcomes included virological suppression (VS; &lt;\u00a050 copies\/mL) and discontinuations (W48 and W96). Estimates were calculated for VF, VS as per snapshot (VSS) and on treatment analysis (VSOT), and discontinuations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pooled mean estimates of VF for DTG\u00a0+\u00a03TC and DTG\u00a0+\u00a0RPV were 0.8% [95% confidence interval (CI): 0.4\u20131.3] and 0.6% (95% CI: 0.0\u20131.6), respectively, at W48. VSS rate at W48 was 85.0% (95% CI: 82.3\u201387.5) for DTG\u00a0+\u00a03TC regimen and 92.4% (95% CI: 85.0\u201397.7) in the DTG\u00a0+\u00a0RPV regimen. The DTG\u00a0+\u00a03TC and DTG\u00a0+\u00a0RPV regimens led to discontinuations in 13.6% (95% CI: 11.1\u201316.2) and 7.2% (95% CI: 2.1\u201314.4) of patients, respectively, at W48. Similar results were observed at W96.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Treatment with DTG\u00a0+\u00a03TC or DTG\u00a0+\u00a0RPV in clinical practice provides a low rate of VF and a high rate of VS when initiated in virologically suppressed PLHIV with diverse backgrounds.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13050","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T03:45:31Z","timestamp":1612583131000},"page":"423-433","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Effectiveness and safety of dolutegravir two\u2010drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta\u2010analysis of real\u2010world evidence"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7531-1319","authenticated-orcid":false,"given":"Y S","family":"Punekar","sequence":"first","affiliation":[{"name":"ViiV Healthcare Brentford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Parks","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Joshi","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Knowledge Centre Gurgaon India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kaur","sequence":"additional","affiliation":[{"name":"Parexel India Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Evitt","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Brentford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Chounta","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Brentford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Radford","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Brentford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Jha","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Knowledge Centre Gurgaon India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ferrante","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sharma","sequence":"additional","affiliation":[{"name":"Parexel India Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Van Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Brentford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"de Ruiter","sequence":"additional","affiliation":[{"name":"ViiV Healthcare Brentford UK"},{"name":"Guy\u2019s and St Thomas\u2019 NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"European AIDS Clinical Society (EACS).European aids clinical society guidelines version 10.0. Available from:https:\/\/www.eacsociety.org\/files\/2019_guidelines\u201010.0_final.pdf(accessed 17 July 2020)."},{"key":"e_1_2_9_3_1","unstructured":"WHO.The use of antiretroviral drugs for treating and preventing HIV infection. Available from:http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208825\/9789241549684_eng.pdf?sequence=1(accessed December 5 2019)."},{"key":"e_1_2_9_4_1","unstructured":"WHO.Updated recommendations on first\u2010line and second\u2010line antiretroviral regimens and post\u2010exposure prophylaxis and recommendations on early infant diagnosis of HIV. Available from:http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273632\/WHO\u2010CDS\u2010HIV\u201018.18\u2010eng.pdf?ua=1(accessed December 5 2019)."},{"key":"e_1_2_9_5_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Available from.https:\/\/aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL003533.pdf(accessed December 5 2019)."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874325001711010777"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/655681"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328339fe53"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328351f68f"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2902"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012268"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X13666171129170046"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0093-9"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013504075"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30015-7"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30091-1"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3975-6"},{"key":"e_1_2_9_18_1","unstructured":"Dolutegravir (tivicay) prescribing information. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204790s016s018lbl.pdf(accessed 29 October 2018)."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222229"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15995.1"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral\u2010naive adults with hiv\u20101 infection (gemini\u20101 and gemini\u20102): Week 48 results from two multicentre, double\u2010blind, randomised, non\u2010inferiority, phase 3 trials","volume":"393","author":"Cahn P","year":"2018","journal-title":"Lancet"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.01.21678"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1083"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S140767"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1457648"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"e_1_2_9_27_1","unstructured":"Van WykJ AjanaF BisshopFet al.Switching to DTG+3tc fixed dose combination (FDC) is non\u2010inferior to continuing a TAF\u2010based regimen (TBR) in maintaining virologic suppression through 24 weeks (TANGO study). 10th International AIDS Conference for HIV Science (IAS 2019). Mexico City Mexico 21\u201324 July 2019."},{"key":"e_1_2_9_28_1","unstructured":"ViiV Healthcare.ViiV healthcare announces positive week 48 results in first study to evaluate treatment switch from TAF\u2010containing regimen with three or more drugs to 2\u2010drug regimen of dolutegravir\/lamivudine for HIV\u20101 infection. Press Release 2019."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.52.6.377"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_9_32_1","unstructured":"Perez\u2010LatorreL TejerinaF TeresaAet al.Efficacy of the combination dolutegravir and rilpivirine as simplification in patients with prior virological failure [abstract p\u2010208]. VIII Congreso Nacional de GeSIDA. San Sebasti\u00e1n Spain 29 November\u20132 December 2016."},{"key":"e_1_2_9_33_1","unstructured":"Services USDoHaH.Guidance for industry: Human immunodeficiency virus\u20101 infection: Developing antiretroviral drugs for treatment. Available from:http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM355128.pdf(accessed 11 February 2019)."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz009"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105893"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016813"},{"key":"e_1_2_9_37_1","first-page":"68","article-title":"Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment experienced HIV\u2010infected patients: 96 weeks results from maintenance dolulam study","volume":"19","author":"Reynes J","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_9_38_1","unstructured":"GagliardiniR LorenziniP Cozzi\u2010LepriAet al.Effect of past virological failure on dolutegravir+lamivudine as maintenance regimen.https:\/\/www.croiconference.org\/abstract\/effect\u2010of\u2010past\u2010virological\u2010failure\u2010on\u2010dolutegravirlamivudine\u2010as\u2010maintenance\u2010regimen\/ 2020."},{"key":"e_1_2_9_39_1","unstructured":"DiazA CasadoJL DrondaFet al.Dolutegravir plus rilpivirine in suppressed heavily pre\u2010treated HIV\u2010infected patients [abstract tupdb0 106]. 21st International AIDS Conference Durban South Africa 18\u201322 July 2016."},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2019.1628460"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017728294"},{"key":"e_1_2_9_42_1","doi-asserted-by":"crossref","unstructured":"SalingC SzabelaME BrownM JohnsonT SisonR SlimJ.Dolutegravir 50 mg + rilpivirine 25 mg (dtv + rpv) daily in treatment \u2010experienced hiv\u2010infected patients [abstract 1519]. Open Forum Infect Dis 2016; 3.","DOI":"10.1093\/ofid\/ofw172.1221"},{"key":"e_1_2_9_43_1","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed\u2010dose two\u2010drug regimen versus continuing a tenofovir alafenamide\u2010based three\u2010 or four\u2010drug regimen for maintenance of virologic suppression in adults with HIV\u20101: Phase 3, randomized, non\u2010inferiority tango study","volume":"71","author":"Wyk J","year":"2020","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1131"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz330"},{"key":"e_1_2_9_46_1","unstructured":"RestelliS RomeriF PiscagliaMet al.Determinants and outcomes of the choice to switch to dolutegravir within different three\u2010 or two\u2010drug regimens in a single\u2010centre cohort: The dolutility study. International Congress of Drug Therapy in HIV Infection. Glasgow UK 2018."},{"key":"e_1_2_9_47_1","first-page":"e25187","article-title":"Virological outcome after switching a suppressive haart to dolutegravir (dtg) with 2 nrtis among hiv\u20101 infected patients: Potential effects of previous suboptimal therapies or previous virologic failures","volume":"21","author":"Sangare M","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049936120901395"},{"key":"e_1_2_9_49_1","unstructured":"ReynesJ MeftahN TuaillonE CharpentiersC MontesB.Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment experienced hiv\u2010infected patients: 96 weeks results from maintenance Dolulam study. 9th International AIDS Society Conference on HIV Science (IAS 2017). Paris France 2017."},{"key":"e_1_2_9_50_1","unstructured":"DeschanvresC RaffiF ReynesJet al.Virologic failure and resistance in dolutegravir\u2010based maintenance dual regimens.https:\/\/www.croiconference.org\/abstract\/virologic\u2010failure\u2010and\u2010resistance\u2010in\u2010dolutegravir\u2010based\u2010maintenance\u2010dual\u2010regimens\/ 2020."},{"key":"e_1_2_9_51_1","unstructured":"BonijolyT CabieA CheretAet al. Week\u201048 efficacy and safety of dolutegravir + rilpivirine dual therapy as a switch strategy in a real\u2010life cohort study.http:\/\/resourcelibrary.eacs.cyim.com\/mediatheque\/media.aspx?mediaId=34526&channel=28172 2017."},{"key":"e_1_2_9_52_1","first-page":"42","article-title":"Treatment outcome for nrti sparing regimen consisting of dolutegravir and rilpivirine [abstract]","volume":"3","author":"Togami H","year":"2016","journal-title":"Reviews in Antiviral Therapy Infectious Diseases"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3270"},{"key":"e_1_2_9_54_1","unstructured":"Grabmeier\u2010Pfistershammer K.Maintenance therapy with dolutegravir\/rilpivirine is efficient and well tolerated in a real\u2010life setting [abstract #o_09]. 2nd European HIV Clinical Forum. Glasgow UK 2 October 2016 2016."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13050","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.13050","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T12:35:16Z","timestamp":1693398916000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/hiv.13050"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13050","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"2020-12-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}